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Abstract
Introduction Data on the characteristics of female
patients counselled for fertility preservation and the effi-
cacy and risk of the applied procedures are still poor. We
therefore analysed the registry of a network of 70 infertility
centers which are involved in fertility preservation in
Germany, Switzerland and Austria, called FertiPROTEKT
(hhtp://www.fertiprotekt.eu).
Materials and methods 1,280 counselled patients (15–40
years) were analysed regarding characteristics and different
fertility preservation treatments before cytotoxic therapy in
2007–2009.
Results 34.8% of the counselled patients were diagnosed
with breast cancer, 30.5% with Hodgkin’s lymphoma, 25.4%
with other malignancies and 9.3% with non-malignant dis-
eases. 89.6% of the treated breast cancer patients were
25–40 years of age, and 87.5% of the lymphoma patients
were 15–30 years of age. At the time of counselling, 85.3%
of the breast cancer patients and 92.7% of the lymphoma
patients were childless.
1,080 patients received a single or combined therapy such
as GnRH agonists (n = 823), cryopreservation of ovarian
tissue (n = 500), ovarian stimulation (n = 221) and
transposition of the ovaries (n = 24). Only one severe
complication, requiring postponement of the chemother-
apy, was documented. In stimulated patients, 2,417 oocytes
(mean n = 11.6, SD ± 7.7) were received. Fertilisation
rate per received oocyte was 61.3%.
Conclusions Fertility preservation programmes mainly
involve women without children, diagnosed with breast
cancer or Hodgkin’s lymphoma. Fertility preservation
techniques can be applied with low risk. The limited and
age-dependant success rate of the different therapies
require individualised approaches of single or combined
fertility preservation techniques.
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Introduction
Increasing survival rates after cancer, new reproductive
techniques and growing interest regarding the quality of
life after cancer and after chemotherapy to treat other
benign systemic disease have brought the possibilities of
fertility preserving treatment to the centre of attention of
oncologists and the affected female patients. Many of these
women suffer from infertility and premature menopause as
a result of chemotherapy and/or radiotherapy to the small
pelvis.
As approximately 70% of patients indicate a prospective
desire for children after completion of chemotherapy [1, 2],
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fertility preservation procedures are of particular relevance,
however, only a few oncologists refer patients to a spe-
cialist in reproductive medicine to take steps to preserve
fertility [3].
Methods of fertility preservation by ovarian protection
include the administration of gonadotrophin agonists
(GnRH-a) [4, 5], cryoconservation with later re-transplan-
tation of the ovarian tissue [6] and hormonal stimulation to
retrieve oocytes with subsequent cryoconservation of
fertilised or unfertilised egg cells and transposition of the
ovaries before radiotherapy to the small pelvis [7].
The various methods can also be combined with one
another [8]. Experience with these techniques and data
about their efficacy and risks are, however, still limited,
which may be an important reason for the limited growth of
fertility preservation procedures. The limited data hinders
balanced patient counselling and the individual integration
of fertility preservation techniques into the oncological
treatment regimen.
Extensive representative registers from networks on the
implementation of fertility protection techniques allow the
possibility of reducing this data deficit. The FertiPRO-
TEKT network (http://www.fertiprotekt.eu) [9] is one
particularly extensive network with a register. The network
was established in 2006 and includes around 70 centres in
Germany, Switzerland and Austria. The aim is the pooling
of expertise from oncologists, rheumatologists and repro-
ductive medicine specialists, and the implementation of a
comprehensive national care structure and development of
obligatory treatment recommendations and standardised
counselling structures. Compulsory documentation of all
patients and treatments has been made since 2007.
We analysed the data from this register for the first time
to obtain solid data on the characteristics of the counselled
and treated patients, about the efficacy of ovarian stimu-
lation treatment in particular, and about the complication
rates from performing fertility preservation techniques.
Materials and methods
The retrospective analysis includes FertiPROTEKT net-
work data from patients aged between 15 and 40 years of
age, who presented for counselling on and treatment with
fertility preservation techniques prior to receiving chemo-
therapy between 01.01.2007 and 31.12 2009 in member
centres of the network.
The 1,388 registers were screened and checked. Missing
details, which should have been analysed in this study or
inconsistent data were not considered. 9.2% of the records
(n = 108) were excluded, and 1,280 records remained for
the analysis.
Specialists in reproductive medicine from the network
advised the patients and their partners depending on
tumour characteristics, ovarian toxicity of the chemother-
apy, the patient’s wishes, and the counselling and manda-
tory treatment standards prepared by the network with
regard to risks, chances of pregnancy and cost of the fer-
tility preserving techniques. The fertility preservation
techniques were incorporated into the treatment regimen in
agreement with the responsible doctors.
The treatment recommendations are available on the
network’s website (http://www.fertiprotekt.eu), and can be
summarised as follows.
GnRH analogues (GnRH-a) used are goserelin (Zoladex;
Astra-Zeneca, Wedel, Germany) or leuprorelin (Enantone;
Takeda Pharma, Aachen, Germany), as a depot injection
for the duration of the chemotherapy.
Removal of ovarian tissue, when possible, is performed
laparoscopically and coagulation of the removed tissue is
avoided. The amount of tissue removed depends on the
anticipated damage to the ovaries. Ovarian tissue was
cryopreserved by slow freezing.
Either an agonist-short-protocol (GnRH-a), an antago-
nist protocol (GnRH-anta) or in the case of stimulation in
the luteal phase, a modified antagonist protocol (mGnRH-
anta) [10] are used for hormonal stimulation to retrieve
oocytes. Vaginal follicle puncture is performed 36 h after
induction of ovulation. If the patient has a long-term
partner, the oocytes are fertilised and cryoconserved at the
pronuclear stage (PN) according to German national law.
In the case of ovarian transposition, the ovaries are
mobilised uni-or bilaterally in order to relocate them cra-
nially and laterally and to fix them to the peritoneum.
Results
Patients
The indication for counselling was a malignancy in 90.7%
of the patients and a benign systemic illness in 9.3%. The
mean age of the counselled and treated patients was 27.8
and 27.4 years, respectively (range 15–40, SD ± 7.0 and
range 15–40, SD ± 6.8).
The two most common malignancies were breast cancer
and lymphoma, and therefore the data was analysed sepa-
rately for these disorders. 89.6% of the breast cancer
patients who decided on fertility preservation treatment
were between 25 and 40 years of age, and 87.5% of the
lymphoma patients were between 15 and 30 years of age.
At the time of counselling, 85.3% of the breast cancer
patients and 92.7% of the lymphoma patients were
childless.
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The characteristics (disease, parity, age) of the coun-
selled and treated patients are shown in Table 1.
Implementation of fertility preservation techniques
After counselling, a total of 84.3% of all patients decided
on one or on a combination of various fertility preservation
methods. This equated to 77.6% of breast cancer and
92.3% of lymphoma patients.
A total of 1,568 procedures, alone or in combination,
were performed.
The most common treatment was administration of
GnRH-a (n = 823), followed by removal of ovarian tissue
for cryoconservation (n = 500). Ovarian stimulation to
retrieve oocytes was the third most common method
(n = 221). Figure 1 shows the utilization of the methods,
also differentiated for patients with all indications and for
patients with breast cancer or lymphoma.
In the patient group who were only treated with one
fertility preservation technique, administration of GnRH-a
(n = 471) was—in analogy to all the treatments per-
formed—the most commonly used technique, followed by
cryoconservation of ovarian tissue (n = 241) and ovarian
stimulation (n = 72). The use of the techniques varied
depending on the different tumour characteristics.
To increase the efficacy of the fertility preservation
techniques, they were combined with one another to some
extent. The most commonly used combination (n = 211)
was administration of a GnRH-a with removal of ovarian
tissue, followed by administration of GnRH with hormonal
stimulation (n = 116). Other combinations were: GnRH-a
plus ovarian stimulation plus removal of ovarian tissue,
GnRH-a plus ovarian transposition plus ovarian stimulation
and ovarian stimulation plus removal of ovarian tissue.
Hormonal stimulation to remove oocytes
Data from 205 follicle punctures were analysed.
The mean stimulation duration was 10.9 days (SD ±
2.6); the mean stimulation dose per day was 225 IE/day
(SD ± 59 IE/day) with a mean total stimulation medica-
tion dose of 2,465 IE (SD ± 875 IE).
A total of 2,417 oocytes were removed (range 0–41,
mean n = 11.6, median n = 10, STD ± 7.7, 25% quartile
n = 6, 75% quartile n = 15), 932 oocytes could be ferti-
lised and 773 were cryoconserved unfertilised.
ICSI was performed with all oocytes from 125 follicle
punctures, and the fertilised oocytes were cryoconserved in
the pronuclear stage (Fig. 2). 1,375 oocytes were retrieved
(range 1–41, mean n = 11.0, median n = 10.0, SD ± 6.6,
25% quartile n = 6, 75% quartile n = 14) and 843 were
successfully fertilised (range 1–27, mean n = 6.7, median
n = 6.0, SD ± 4.8, 25% quartile n = 3, 75% quartile
n = 9). The fertility rate per removed oocyte was 61.3%.
Complications
Complications of fertility preservation techniques were:
• Events which led to the postponement of the start of
chemotherapy
• Termination of ovarian stimulation
• Ovarian stimulation without oocyte retrieval or without
fertilisation.
There were 8 events from a total of 1,568 fertility
preservation procedures which were classified as compli-
cations, which is equivalent to a risk of 0.74% per treated
patient. The risk of a complication occurring was 2.9% per
stimulated patient during the course of ovarian stimulation,
0.4% per patient for ovarian tissue removal and 0.08% per
treated patient when the start of chemotherapy was
postponed.
The complications and their consequences for the start
of chemotherapy are listed in Table 2.
Discussion
Depending on the age of the patient and the agents used,
chemotherapy can lead to damage to ovarian function and
Table 1 Characteristics (disease, parity, age) of the counselled and
treated patients
Number of patients
Counselling Treatment
Counselling indication
Breast cancer 446 (34.8%) 346 (32.0%)
Lymphoma 390 (30.5%) 360 (33.3%)
Other malignant diseasea 325 (25.4%) 269 (24.9%)
Benign illnessb 119 (9.3%) 105 (9.7%)
Total 1,280 (100%) 1,080 (100%)
Number of children
No children 1,102 (86.1%) 944 (87.4%)
1 or more children 178 (13.9%) 136 (12.6%)
Total 1,280 (100%) 1,080 (100%)
Age (years)
15–25 468 (36.5%) 423 (39.1%)
26–35 655 (51.2%) 534 (49.4%)
36–40 157 (12.3%) 123 (11.4%)
Total 1,280 (100%) 1,080 (100%)
a Cancer of the gastrointestinal tract, gynaecological cancers, germ-
cell carcinomas, melanomas, neurological cancers, sarcoma
b Benign haematological disorders, Turner syndrome, immunological
disorders, auto-immune disorders, systemic lupus erythematosus
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loss of fertility [11–13]. The implementation of fertility
preservation techniques in the treatment regimen is there-
fore of great importance. Analysis of the data from the
FertiPROTEKT network revealed for the first time both the
counselling indications, age distribution and parity of the
counselled and treated patients and also the choice, efficacy
and safety of the fertility preservation methods prior to
chemotherapy in a large number of patients. These data can
be useful when developing fertility protection programmes,
for example to better define the patient structure and target
groups, and also to help when counselling couples. The
data also reflect the realistic situation in a large multi-
centre programme. As highly specialised as well as less
specialised centres are represented in this programme, the
success and complication rates described depict realisti-
cally achievable targets.
Of the patients who presented for counselling in the
FertiPROTEKT network and who underwent fertility
protection treatments, 86.1% (counselling) and 87.4%
(treatment) were childless, and at counselling and treat-
ment had a mean age of 27.83 and 27.35 years,
respectively. A study by Klock et al. [14] also showed
a prevalence of childless patients at counselling and
treatment.
We recorded the age distribution of the counselled and
fertility protection-treated patients independently of the
choice of fertility preservation technique. This realistically
reflects the age distribution of the patients for whom a need
for fertility preservation counselling exists. Thus, patients
who decided on cryoconservation of an entire ovary were,
on average, 25.4 years of age (range 9–37) [15]; in con-
trast, patients who underwent hormonal stimulation to
retrieve oocytes were 32.3 ± 5.0 years of age [16]. The
mean age of the our collective of treated women was
27.35 years, yet 89.6% of the women with breast cancer
were aged 25–40 years and 87.5% of women with a lym-
phoma were aged 15–30.
The largest group of counselled patients was made up of
patients with breast cancer (34.8%), followed by patients
with a lymphoma (30.5%). In contrast, the most treatments
within one disease group were performed on lymphoma
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patients (33.3%). This data is in agreement with other
studies [14–19].
Up to now, the choice of fertility preservation technique
has only been studied in small collectives. Oktay et al. [18]
and Klock et al. [14] evaluated data from 462 and 65 patients,
respectively: in patients who decided on fertility preserva-
tion treatment, 50.6 and 85% underwent embryo cryocon-
servation, respectively, and 26.6 and 4.9% underwent
removal of ovarian tissue, respectively. Our data analysis
shows that 26.6% of breast cancer patients and 16.1% of
lymphoma patients decided on hormonal stimulation to
retrieve oocytes, and 60.4% of breast cancer patients and
33.3% of lymphoma patients for ovarian tissue removal. The
reason for the high proportion of patients choosing cryo-
preservation of ovarian tissue instead of ovarian stimulation
might be the fear of breast cancer patients of a negative
influence of the hormonal stimulation upon the prognosis of
the breast cancer, the higher cost of ovarian stimulation and
the time consuming ovarian stimulations. However, as
shown in this paper, ovarian stimulation and cryopreserva-
tion of fertilised oocytes is a well established and successful
technique and should be the first choice in fertility preser-
vation programmes.
Neither of the studies referred to above [14, 18] recorded
administration of GnRH-a. Up to now, the efficacy of
GnRH-a application for ovarian protection is still contro-
versial. A recently published review by Dittrich et al. [23]
summarises the inconsistent data. Despite the unclear effi-
cacy, this was the most common treatment option in our
collective, as an individual treatment as well as in combi-
nation, followed by ovarian tissue removal and hormonal
stimulation. Removal and transplantation of ovarian tissue
has also been performed frequently, as the procedure is
performed within a few days and as it has already been shown
to be successful, though still experimental [24].
No other investigation includes the combination of fer-
tility preservation techniques. The combination of an
invasive method (ovarian tissue removal, hormonal stim-
ulation) with GnRH-a does not increase the intervention
risk for the patient. Huober-Zeeb et al. [8] showed that the
combination of ovarian tissue removal with subsequent
hormonal stimulation can be carried out with good efficacy
and without threat to the patient.
Implementation without additional risks for the patient
is of great importance for the integration of fertility pres-
ervation techniques into the oncological treatment concept;
therefore, recording of complications is intrinsically
important.
Of the 500 patients who underwent ovarian tissue
removal, perioperative complications occurred in only
0.4%. This low complication rate is confirmed in work
by Rosendahl et al. (4.3%) [15] and Oktay et al. (0%)
[20].
Ovarian stimulation to remove oocytes can also be
performed with a very low risk for the patient: none of our
collective developed ovarian hyperstimulation syndrome
(OHSS) which led to postponement of the start of che-
motherapy. In 2.9% of stimulated patients, stimulation had
to be stopped because of low response, or because no egg
cells could be removed during follicle puncture. Other
studies with small case numbers [14, 16–18] report termi-
nation or low response rates as being between 7.1 and 18%.
Our results from ovarian stimulation treatment before
chemotherapy are both comparable with the results from
other studies, which to some extent used significantly
higher stimulation doses [14, 16, 17, 21], and also with the
stimulation results from conventional infertility treatment.
The fertility rate in patients who, together with their part-
ner, decided upon cryoconservation of the fertilised egg
cell was 61.3% per removed oocyte in the total collective.
Table 2 Complications during fertility preservation treatments
Age (years) Illness Complication Postponement of chemotherapy
Complications during ovarian stimulation
36 Breast cancer Termination of stimulation No
19 AML Termination of stimulation No
34 Breast cancer No follicle puncture followed No
37 Medulloblastoma No egg cells retrieved No
36 SLE No egg cells retrieved No
27 Hodgkin’s lymphoma No fertilisation occurred No
Complications during ovarian tissue removal for cryoconservation
19 Nephroblastoma No tissue removal possible due to adhesions No
34 Lymphoma Laparotomy because of secondary haemorrhage Postponement of start
of chemotherapy by 5 days
AML acute myeloid leukaemia, SLE systemic lupus erythematosus
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To compare efficacy, data from the German IVF Reg-
ister (DIR) were consulted. The DIR collects data from all
German centres for reproductive medicine. 40,816 IVF/
ICSI treatment cycles were performed in 2008; a mean of
9.5 oocytes were collected per stimulation cycles inde-
pendent of age, and the fertilisation rate was 58.6% after
IVF and 66.7% after ICSI [22].
Analysis of counselling and treatment data from the
FertiPROTEKT network shows that primarily women who
are childless at the time of their treatment access coun-
selling and treatment with fertility preservation techniques.
The techniques can be performed, alone or in combination,
with a low risk of acute complications occurring. For
ovarian stimulation in particular, the mean success rate and
also the high range can be quantified using this data.
Finally, the data emphasise that fertility preservation
treatment can be and should be individualised and ideally
performed as a combination of different techniques in order
to increase its efficacy.
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